Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI – Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 44,400 shares, an increase of 114.5% from the June 30th total of 20,700 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is presently 0.0 days.
Scinai Immunotherapeutics Trading Up 15.6 %
NASDAQ:SCNI traded up $0.59 during mid-day trading on Friday, hitting $4.36. The stock had a trading volume of 193,624 shares, compared to its average volume of 1,592,664. The stock has a market capitalization of $2.01 million, a price-to-earnings ratio of -0.02 and a beta of 2.50. The company has a 50 day simple moving average of $3.70 and a 200-day simple moving average of $4.47. Scinai Immunotherapeutics has a 52 week low of $2.23 and a 52 week high of $14.20.
Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) last issued its quarterly earnings data on Tuesday, July 2nd. The company reported ($4.00) earnings per share for the quarter.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
See Also
- Five stocks we like better than Scinai Immunotherapeutics
- What is Forex and How Does it Work?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How to buy stock: A step-by-step guide for beginners
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is the Hang Seng index?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.